The risk of severe spondyloarthritis (SpA)-associated enthesitis/osteitis following successful therapy with vedolizumab for IBD has been highlighted in a small case series. The study, published in Rheumatology, found de novo SpA in 9 of 11 patients and flare of known SpA in two of the 11 patients who developed severe active SpA and/or enthesopathy on vedolizumab. ...
Multidisciplinary approach needed for vedolizumab-linked SpA enthesitis/osteitis
By Mardi Chapman
26 Feb 2019